Cardiology Pharmaceuticals

Aprocitentan: The New Antihypertensive on the Block

blood pressure
blood pressure

Aprocitentan has proved itself a promising new agent for blood pressure control. In the 730-patient PRECISION trial, aprocitentan (Idorsia Pharmaceuticals) lowered both office and 24-hour ambulatory BP among people with resistant hypertension. 

Clinicians usually treat resistant hypertension with the general diuretic spironolactone, which targets the renin-angiotensin-aldosterone system. But aprocitentan, a dual endothelin receptor antagonist, works on the endothelin pathway –  a previously untapped avenue to BP control. 

PRECISION was a blinded, randomized, placebo-controlled, phase 3 trial conducted in Europe, Asia, Australia, and North America. The study consisted of three consecutive parts:

  • In part 1, patients were randomized to take either 12.5 or 25 mg aprocitentan, or placebo, for four weeks. 
  • In part 2, all patients took aprocitentan 25 mg for 32 weeks.
  • In part 3, patients were rerandomized to aprocitentan 25 mg or placebo for 12 weeks. 

At the end of part 1, patients who took 12.5 and 25 mg aprocitentan saw the following placebo-adjusted blood pressure drops: 

  • Office systolic BP decreased by 3.8 and 3.7 mmHg
  • Office diastolic BP decreased by 3.9 and 4.5 mmHg
  • 24h ambulatory systolic BP dropped by 4.2 and 5.9 mmHg

By the end of part 2, patients showed sustained BP reduction for all 32 weeks. 

At the end of part 3, BP rose in patients who had switched from taking 25 mg aprocitentan to placebo. For those who continued taking aprocitentan, their reduced BP level was maintained. 

Edema was the most common side effect during the initial four weeks (9.1% w/ 12.5 mg, 18.4% w/ 25 mg), although the authors said this could be easily managed with diuretics. 

Notably, the Lancet reviewers held a more skeptical view, questioning whether the result was clinically significant, especially in light of the high rate of edema. They conclude that the utility of aprocitentan remains unclear, particularly compared to existing options like spironolactone. 

The Takeaway

This appears to be a win for aprocitentan, especially since it offers a novel mechanism for BP reduction in patients with resistant hypertension, even if more research is needed to know for sure. 

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Heart Failure October 20, 2025

Don’t Blame Your Heart for Heart Failure October 20, 2025

Perhaps the biggest cardiology story of the year, an entire issue of JACC now hypothesizes that heart failure with preserved ejection fraction (HFpEF) might actually be caused by visceral fat tissue that triggers cardiac weakening through adipokine signaling. The new unifying adiposity framework now proposes that visceral fat expansion causes secretion of an altered adipokine […]

Cardiology Business October 16, 2025

MedAxiom Report: Cardiologist Compensation Soars, Patient Access Struggles October 16, 2025

Good news and bad news from MedAxiom’s latest cardiology compensation survey. The good news? Cardiologist median compensation reached new record highs last year. The bad news? Patient access deteriorated while the number of patients physicians had to manage swelled. The 2025 survey findings aggregated data across cardiology, cardiac surgery, and vascular surgery specialties, examining compensation […]

Heart Failure October 13, 2025

Specialist Care Can Improve HF Outcomes Across the Board October 13, 2025

A recent study out of the U.K. suggests that multidisciplinary team management could significantly reduce death or rehospitalization risk for HF patients across the LVEF spectrum. Based in a single U.K. county, the Buckinghamshire analysis examined 2.1k patients hospitalized for acute heart failure who received either specialist care or standard care over a 618-day follow-up […]